Brought to you by 
Avalon Ventures provides Zacharon with $3.5mm in first round
25 Nov 2008
Executive Summary
Zacharon Pharmaceuticals (diseases caused by glycan accumulation) raised $3.5mm in its Series A round from sole investor Avalon Ventures. Members of the VC firm have joined the executive management of the biotech company.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Avalon Ventures provides Zacharon with $3.5mm in first round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice